Holen Sie sich die Stockscreener-App
5.84
3.36%
0.18
Schlusskurs vom Vortag:
$5.66
Offen:
$5.7
24-Stunden-Volumen:
1.66M
Relative Volume:
0.38
Marktkapitalisierung:
$1.43B
Einnahmen:
$407.32M
Nettoeinkommen (Verlust:
$-61.60M
KGV:
-22.67
EPS:
-0.2576
Netto-Cashflow:
$-43.98M
1W Leistung:
-5.49%
1M Leistung:
-14.85%
6M Leistung:
-11.50%
1J Leistung:
+7.93%
1-Tages-Spanne:
$5.65
$5.895
1-Wochen-Bereich:
$5.60
$6.378
52-Wochen-Spanne:
$3.21
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.845 | 1.39B | 407.32M | -61.60M | -43.98M | -0.2576 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.48 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.03 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.62 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.69 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.44 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-02 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2025-03-04 | Eingeleitet | BTIG Research | Buy |
| 2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
| 2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-23 | Eingeleitet | Wedbush | Outperform |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Fortgesetzt | Citigroup | Buy |
| 2020-02-18 | Fortgesetzt | Jefferies | Buy |
| 2020-02-12 | Eingeleitet | Citigroup | Buy |
| 2020-02-10 | Eingeleitet | Cowen | Outperform |
| 2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-24 | Eingeleitet | Jefferies | Buy |
| 2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-29 | Bestätigt | Citigroup | Buy |
| 2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
| 2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
Leerink Maintains Outperform on Ardelyx, Inc (ARDX) March 12, 2026 - Meyka
Leerink Partners reiterates Ardelyx stock rating on pipeline progress - Investing.com
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award - The Manila Times
Five kidney disease advocates honored for decades of patient support - Stock Titan
Breakout Move: How does Ardelyx Inc correlate with Nasdaq2026 Highlights & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Ardelyx Touts IBSRELA’s 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan - MarketBeat
Ardelyx at Leerink Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
ARDX: IBSRELA targets $1B sales by 2029, with pipeline and commercial growth fueled by strong execution - TradingView
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Weakness - Yahoo Finance
Ardelyx (ARDX) Valuation Check After Recent Share Price Weakness And Growth Expectations - simplywall.st
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C - The Manila Times
Ardelyx, Inc. Publishes Data Supporting Tenapanor's Rapid and Sustained Relief for IBS-C in Peer-Reviewed Journal - Quiver Quantitative
New IBS-C analysis: tenapanor brings relief within weeks - Stock Titan
Ardelyx gains after insider purchase, LPGA marketing deal - MSN
Is Ardelyx (ARDX) Pricing In Its Potential After Recent Share Price Weakness - Yahoo Finance
Is Ardelyx (ARDX) Pricing Reflect Its DCF Upside After Recent Share Price Volatility - simplywall.st
Ardelyx's post-earnings decline attributed to concerns over Ibsrela outlook - MSN
Is Ardelyx Inc. (41X) stock bottoming after sell off2026 Buyback Activity & Technical Pattern Based Buy Signals - Naître et grandir
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Ardelyx’s 2026 IBSRELA Outlook Altering The Investment Case For Ardelyx (ARDX)? - Sahm
Vanguard Group Inc. Boosts Holdings in Ardelyx, Inc. $ARDX - MarketBeat
Biotech firm Ardelyx heads to Miami for back-to-back investor events - Stock Titan
ARDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ardelyx (NASDAQ:ARDX) Stock Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Ardelyx LPGA Partnership Puts Spotlight On Women’s Digestive Health And Growth - simplywall.st
Ardelyx to Participate in Upcoming Investor Conferences - The Manila Times
Assessing Ardelyx (ARDX) Valuation After Strong 2025 Results And 2026 Growth Guidance - simplywall.st
Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership - The Globe and Mail
Revisiting ArdelyxInsider Weekends (NASDAQ:ARDX) - Seeking Alpha
ARDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ardelyx, Inc. (ARDX) Investor Outlook: Analysts See A Potential 142% Upside - DirectorsTalk Interviews
Ardelyx goes full swing with the LPGA for IBS-C awareness - Medical Marketing and Media
ARDELYX (NASDAQ: ARDX) CEO Raab sells 41,666 shares after option exercise - Stock Titan
Ardelyx (ARDX) Price Target Increased by 10.08% to 16.20 - Nasdaq
Ardelyx (ARDX) Partners with LPGA to Promote IBS-C Awareness - GuruFocus
Proposed ARDX share sales and insider sale (ARDX) by Michael G. Raab - Stock Titan
Ardelyx Becomes Marketing Partner of Ladies Professional Golf Association - marketscreener.com
Hedge Fund and Insider Trading News: Paul Singer, David Tepper, Warren Buffett, Bill Ackman, Caxton Associates, Bridgewater Associates, Hycroft Mining Holding Corporation (HYMC), Ardelyx Inc (ARDX), and More - Insider Monkey
Insider Stock Purchases: February 24, 2026 - Quiver Quantitative
Ardelyx, Inc. Stock Hits Day Low of $5.55 Amid Price Pressure - Markets Mojo
Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity - MarketBeat
Ardelyx gains after insider purchase (update) (ARDX:NASDAQ) - Seeking Alpha
Is Ardelyx Inc. stock a buy or sell2025 Volatility Report & AI Enhanced Trading Alerts - mfd.ru
Ardelyx (ARDX) Partners with LPGA to Champion Women's Health - GuruFocus
Ardelyx and the LPGA announce multi-year partnership - marketscreener.com
Ardelyx and the LPGA Announce Multi-Year Partnership to - GlobeNewswire
Ardelyx (ARDX) Is Down 16.3% After Issuing Higher 2026 Product Revenue Guidance and Patent Update - simplywall.st
Ardelyx Insider Bought Shares Worth $1,946,331, According to a Recent SEC Filing - marketscreener.com
ARDX stock jumps over 5% overnight as director loads up in vote of confidence for flagship constipation drug - MSN
Ardelyx (ARDX) Valuation Check After 2025 Results And Strong 2026 Growth Guidance - Yahoo Finance
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):